Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Aplastic Anemia Patients With Immunosuppressive-Therapy Refractory Thrombocytopenia

NCT00922883 is registered in ClinicalTrials.gov with National Heart, Lung, and Blood Institute (NHLBI) as lead sponsor.

NCT NCT00922883
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00922883 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Aplastic Anemia Patients With Immunosuppressive-Therapy Refractory Thrombocytopenia
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Phase
Phase 2
Overall status
Completed
Start date
May 29, 2009
Completion date
April 24, 2018
Enrollment
43 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, aplastic, anemia, hypoplastic, thrombocytopenia